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Abstract
OBJECTIVE: To investigate the effects of ribavirin
administration combined with Reduning in a
mouse model of influenza A (H1N1)-induced se-
vere pneumonia.
METHODS: Influenza A/Beijing/501/2009 (H1N1)-
infected C57BL/6 mice were randomly divided into
four experimental groups treated with either a
mock injection of phosphate-buffered saline (PBS),
ribavirin (66.6 mg/kg daily) or Reduning (86.6 mg/
kg daily), or a combination of both, for 7 days. Mice
were monitored for clinical signs and survival, and
body weight was measured daily for 14 days. Virus
titer, lung wet-to-dry ratios, pathology and cyto-
kines including interleukin (IL)-6, IL-10, and interfer-
on (IFN)-γ were assayed on different days.
RESULTS: In the untreated group injected with
phosphate buffer saline, all the mice died of the in-
fection. The survival rate of mice treated with Re-
duning was only 10%, whereas 100% of the ribavi-
rin- and the combination-treated mice survived.
Low lung viral loads indicated that ribavirin signifi-
cantly inhibited virus replication, whereas Redun-
ing did not. Lung wet-to-dry ratios demonstrated
that both ribavirin and Reduning, administered to-
gether or separately, reduced acute lung edema
compared with results in the untreated group. Pa-
thology analyses also showed that treatment with
a combination of both drugs relieved pathological
lesions, whereas the single drug treatment did not.
Levels of IL-6, IL-10 and IFN-γ in mice treated with
ribavirin or the combination of both ribavirin and
Reduning were all significantly lower than in the
untreated group, especially in the combina-
tion-treated group. In addition, Reduning adminis-
tration significantly decreased both IL-6 and IL-10
production but had no effect on IFN-γ.
CONCLUSION: Due to the synergistic effect of anti-
viral and antiinflammation, the combination of riba-
virin and Reduning could be an effective treatment
for severe H1N1 which was considered to be signifi-
cant to delayed antiviral and drug resistant.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
In April 2009, H1N1 swine flu first emerged in Mexi-
co.1 On August 10th 2010, the World Health Organi-
zation declared influenza A H1N1 (pH1N1) a pan-
demic. During this period, 214 countries reported con-
firmed cases of influenza A H1N1; and the disease re-
sulted in 18 449 deaths. Mainland China alone report-
ed a total of 12.8 million cases with 805 deaths and a
0.5% mortality rate. Some severely infected patients de-
veloped acute pneumonia, which was the predominant
cause of reported deaths. Although the mortality
caused by pH1N1 infection was low, 9%-31% of
pH1N1 patients required admission to intensive care
units, and 14%-46% of these patients ultimately
died.2-5 To this day, the main treatment strategy for se-
vere pneumonia relies on different types of adjunctive
therapies, although those treatments are controversial.
The clinical treatment of pH1N1 mainly depends on
neuraminidase inhibitors such as oseltamivir, and anti-
viral compounds such as ribavirin. However, antiviral
therapy usually involves a delayed response or has low
efficacy.6 Systemic corticosteroids are often used to
treat severe influenza, although several studies have in-
dicated that this may increase the risk of mortality.7
Chinese medicine has been widely used in the treat-
ment of pH1N1. Some drugs such as Shufengjiedu
capsules and Maxingshigan decoctions have shown ef-
fectiveness.8 However, there have been few studies re-
porting the effects of Chinese medicine on severe influ-
enza. Reduning, one clearing heat and detoxifying Tra-
ditional Chinese Medicine (TCM) injection, was maily
used for treatment of acute and severe disease in clini-
cal. Many studies had reported that Reduning could re-
duce the duration of influenza illness which was attrib-
uted to the role in inhibiting NA and anti-inflamation.
Compared with antiviral injections, formulations of
capsules, decoctions, or granules alone have been un-
able to provide immediate relief for severe influenza in
clinical practice. This study investigated the efficacy of
antiviral administration combined with injections of
the Chinese medicine Reduning for the treatment of se-
vere influenza.
MATERIALS ANDMETHODS
Virus, cells and animals
Influenza A/Beijing/501/2009 (H1N1) (BJ501) and
Madin Darby Canine Kidney cells were obtained from
the Beijing Institute of Microbiology and Epidemiolo-
gy, State Key Laboratory of Pathogen and Biosecurity.
Specific pathogen free (SPF) C57BL/6 female mice,
4-6 weeks old (Experimental Animal Production Li-
cense No. SCXK 2012-003), weighing 14-16 g, were
provided by the Laboratory Animal Center of the Acad-
emy of Military Medical Science (Beijing, China).
Drugs and reagents
Ribavirin Injection (Batch No. 1003167, 0.1 g /2 mL)
was obtained from the Shandong Lu Kang Chen Xin
Pharmaceutical Co, Ltd. (Shandong, China). Redun-
ing (Batch No. 1009022, 6 g /10 mL) was purchased
from the Kang Yuan Pharmaceutical Co, Ltd. (Hunan,
China). The mouse inflammatory cytokines cytometric
bead array was obtained from BD Biosciences (Frank-
lin Lakes, NJ, USA).
Therapeutic efficacy of different drugs or
combination against pH1N1 in mice
To evaluate the therapeutic role of ribavirin, Reduning
or both against BJ501 infection, following intraperito-
neal (i.p.) anesthetization with pentobarbital sodium,
C57BL/6 mice received 2 × 105 TCID50 of BJ501 intra-
nasally (i.n.) on day 0 as shown previously 9-10, followed
by i.p. injections of Reduning (86.6 mg·kg－1·d－1), rib-
avirin (66.6 mg·kg－1·d－1), a combination of both, or
a mock injection phosphate buffer saline (PBS) once a
day for 7 days post infection (in order to achieving
theraputic drug concentration once infection, each
group were administered 12 h before infection. Mice
in each group (n = 10) were monitored daily for surviv-
al, clinical signs and body weight. Mice from each
group were euthanized on different days, and the lungs
were collected as described below.
The viral load in the lung tissue of mice
Lung tissues from five mice selected from each group
were collected at 4 days post-infection (DPI). The ti-
ters of viruses in the lung tissue were determined by
the cell culture infective dose 50% (CCID50) assay in
Madin Darby canine kidney cells.9,10
Acute pulmonary edema (wet-to-dry ratio)
Assessment of acute pulmonary edema was performed
at 4 DPI by calculating the lungs' wet-to-dry ratios
from the weights of wet lungs and the dry weight ob-
tained after heating the tissues at 68℃ for 24 h.
Histological examination
Following pentobarbital sodium anesthesia, two to
four mice from each group were sacrificed at 5 DPI.
Lungs were fixed in formalin and embedded in paraf-
fin. Ultrathin sections were obtained and stained with
hematoxylin-eosin. Lung histopathology was deter-
mined by light microscopy (Olympus, Japan).
Cytokine and chemokine measurement
For cytokine measurements, five mice from each group
were euthanized and bronchoalveolar lavage fluids
(BALFs) were collected at 2 and 4 DPI. BALFs were as-
sessed for interleukin (IL)-6, IL-10 and interferon
(IFN)-γ using the cytometric bead array. Array analysis
was performed using FCAP Array software.
182
JTCM |www. journaltcm. com April 15, 2016 |Volume 36 | Issue 2 |
MaYX et al. / Experimental Study
Statistical analyses
All data are shown as means ± standard deviation ( xˉ ± s).
Survival data were analyzed by Kaplan-Meier survival
analysis measurements at single time points and statis-
tics performed using analysis of variance. If they
reached significance, data were further analyzed by a
two-tailed Student's t-test. All statistical tests were con-
ducted using GraphPad Prism 5.0 software (Software
MacKiev, San Diego, CA, USA). P < 0.05 indicates sta-
tistical significance.
RESULTS
Administration of ribavirin and Reduning
ameliorated pH1N1-induced acute influenza
symptoms
At 14 DPI, none of the mice that received the mock in-
jection survived BJ501 infection (0% ). The survival
rate was significantly improved when mice were given
ribavirin (100%), or a combination of ribavirin and Re-
duning (100%). However, administration of only Re-
duning resulted in a low survival rate (10% ) (Figure
1A). Loss in body weight in the PBS group was as high
as 40% with continuous decline until death. However,
mice treated with ribavirin or both ribavirin and Re-
duning showed a weight loss of only 15% , which
stopped declining at 5 DPI and improved at 8 DPI.
The therapeutic efficacy of Reduning alone was very
low; weight loss in this group was 25%, with a late re-
covery in weight that began at 10 DPI (Figure 1B).
When compared to the mice treated with Reduning
alone, both Ribavirin and the combination Ribavirin
and Reduning significantly decreased the body weight
loss induced by BJ501 infection, especially the combi-
nation group (Figure 1C). Acute lung pneumonia, as-
sessed by lung pathology and wet-to-dry weight ratio,
was also improved when mice were treated with either
of the single drugs or both drugs. The pathological ob-
servations showed that both drug treatments improved
lung pathological lesions. At 5 DPI, lungs of PBS-in-
jected mice showed congestion, edema and hemor-
rhage with diffuse inflammatory cell infiltration, shed-
ding and necrosis of alveolar epithelial cells as well as
bronchial epithelial cell degeneration. The lungs of the
mice treated with both ribavirin plus Reduning dis-
played significant improvement with reduced edema,
local alveolar septal thickening and inflammatory cell
infiltration. The lung lesions of the mice treated with
either ribavirin or Reduning were alleviated when com-
pared with the PBS-treated group but not to the extent
of both drugs administered together (Table 6 and Fig-
ure 2). Similarly, wet-to-dry ratios of mice treated with
ribavirin alone or ribavirin and Reduning together
were significantly reduced compared with the
PBS-treated group (Table 1). Notably, the wet-to-dry
ratio of mice treated with Reduning alone was also sig-
nificantly reduced (Table 1).
Administration of both ribavirin and Reduning may
induce a synergistic antiviral and
immunomodulatory effect
Viral load titers in the lungs of mice treated with ribavi-
rin alone or both ribavirin and Reduning were signifi-
cantly decreased, suggesting that both treatment meth-
ods efficiently inhibited virus replication (Table 1).
However, there was no difference in lung BJ501 titers
between the treatment with Reduning alone and PBS
(Table 1).
Compared with the PBS group, administration of riba-
Figure 1 Administration of ribavirin and Re-
duning ameliorated pH1N1-induced acute
influenza symptoms
A: the survival rates of the mice with indi-
cated treatments for 7 successive days (n =
10); B: Body weight changes (n = 10); C:
Body weight changes of the ribavirin and
ribavirin plus Reduning groups. Compared
with the Reduning group, PBS: phos-
phate-buffered saline; aP < 0.05 and bP < 0.01.
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virin, Reduning, or both drugs combined significantly
reduced the levels of IL-6, IL-10 and IFN-γ in BALF
at both 2 and 4 DPI, although the effect on IFN-γ was
much less dramatic in the Reduning-only group (Table
2). Levels of all three cytokines in BALF were similar
in the mice treated with either ribavirin alone or the
combination of ribavirin and Reduning at 4 DPI,
which were significantly lower than in the PBS group.
Furthermore, IL-10 levels were only significantly de-
creased at 2 DPI in the mice that received the com-
bined treatment (Table 2).
DISCUSSION
There is an urgent need for an effective strategy for
treatment of severe influenza. Current recommenda-
tions for influenza treatment primarily focus on allevi-
ating clinical symptoms and restoring respiratory func-
tion.11 Previous autopsy case reports have indicated
that lung injury in severe influenza patients included
serious interstitial lung injury, hyaline membrane for-
mation, alveolar septal edema, alveolar epithelial cell
proliferation, intravascular fibrin thrombosis, and fine
bronchial wall necrosis.12 Some pH1N1 cases in teenag-
ers over 18 years of age without any other diseases have
displayed histological changes similar to those in
Notes: PBS group: infected mice treated with PBS (1 mL) by i.p. injection for 7 days; Reduning group: infected mice treated with Redun-
ing (86.6 mg·kg－1·d－1) by i.p. injection for 7 days; ribavirin group: infected mice treated with ribavirin (66.6 mg·kg－1·d－1, 1 mL) for 7
days; ribavirin plus Reduning: infected mice treated with both ribavirin (66.6 mg·kg－1·d－1, 1 mL) and Reduning (86.6 mg·kg·－1·d－1, 1
mL) for 7 days. Viral loads in lungs were determined in Madin Darby Canine Kidney cells.DPI: days post-infection; PBS: phosphate-buff-
ered saline. All treatment groups compared with PBS group, aP < 0.05.
Group
PBS
Reduning
Ribavirin
Ribavirin plus Reduning
n
5
5
5
5
Wet-to-dry ratios
4 DPI
7.3±0.7
6.2±0.3a
4.7±0.4a
4.6±0.4a
P value
-
0.04
0.00
0.00
Virus titer (logCCID 50 /mL)
4 DPI
4.7±0.3
4.3±0.3
3.3±0.3a
3.8±0.3
P value
-
0.19
0.00
0.00
Table 1Wet-to-dry ratios and viral loads of lungs at 4 days post-infection ( xˉ ± s)
Group
Naive
PBS
Reduning
Ribavirin
Ribavirin plus Reduning
IL-6
2 DPI
18.6±1.2
30.7±3.3a
24.9±2.2b
22.1±3.3b
18.4±3.2b
4 DPI
18.6±1.2
35.4±6.7a
39.0±6.0
24.0±8.6b
17.6±3.1b
IL-10
2 DPI
9.12±1.43
141.9±75.6a
104.1±18.9
85.6±64.6
27.8±7.6 b
4 DPI
9.12±1.43
189.2±36.9a
62.5±44.8b
43.7±16.6b
16.2±13.6b
IFN-γ
2 DPI
22.5±2.6
372.6±209.1a
185.5±27.4
201.9±108.9
143.4±75.7
4 DPI
22.5±2.6
1061.8±759.8a
855.1±66.4
151.1±27.4 b
90.6±17.9 b
Table 2 Concentrations of IL-6 , IL-10 and IFN-γ at 2 and 4 days post infection (pg/mL, ± s)
Notes: Naive group: mice treated with PBS (1 mL) i.p. for 7 days; PBS: infected mice treated with PBS (1 mL) i.p. once a day for 7 days;
Reduning: infected mice treated with Reduning (86.6 mg·kg－1·d－1) once a day for 7 days i.p.; ribavirin: infected mice treated with ribavi-
rin (66.6 mg·kg－1·d－1) once a day for 7 days i.p.; ribavirin plus Reduning: infected mice treated with both ribavirin (86.6 mg·kg－1·d－1)
and Reduning (66.6 mg·kg－1·d－1) once a day for 7 days i.p. Concentrations of IL-6, IL-10, IFN-γ in bronchoalveolar lavage fluids sam-
ples were determined by cytometric bead array. IL: interleukin; IFN-γ: interferon-γ; DPI: days post-infection; PBS: phosphate-buffered sa-
line. PBS group compared with naïve group, aP < 0.05 and all treatment groups compared with the PBS group, bP < 0.05.
Figure 2 Histological findings from lung tissues. Representa-
tive pathological images from the lungs at 5 days post-infec-
tion. The lungs of two to four mice from each group were
fixed in formalin and embedded in paraffin. Ultrathin sec-
tions were obtained and stained with hematoxylin-eosin (×
100)
A: mice treated with PBS showing inflammatory infiltrate
and alveolar damage. B: Mice treated with Reduning for 7
days exhibited no difference from the PBS group in terms of
histopathology. C: Mice treated with ribavirin for 7 days
showed a noticeable reduction in inflammation and tissue
damage compared with the PBS group. D: Mice treated with
ribavirin and Reduning together for 7 daysexhibited the
lightest damage compared with anygroup else. PBS: phos-
phate-buffered saline
A B
C D
184
JTCM |www. journaltcm. com April 15, 2016 |Volume 36 | Issue 2 |
MaYX et al. / Experimental Study
H5N1 infection cases.13 Thus, the prognosis for severe
influenza patients is particularly associated with the se-
verity of lung pathological injuries. Some animal mod-
els have validated the fact that virus replication and im-
mune dysregulation with higher levels of proinflamma-
tory cytokines and chemokines play important roles in
the pathogenesis of severe influenza.14 Nowadays, be-
cause of the slow progress in developing antiviral
agents for influenza, combining available drugs pro-
vides an opportunity to generate a more effective treat-
ment than antiviral drugs alone.15 Adjunctive treat-
ments for influenza, particularly those modulating ex-
cessive pro-inflammatory host responses to infection,
have been shown to be effective.16
As a guanosine analogue, ribavirin is a broad-spectrum
antiviral drug that can inhibit both DNA and RNA vi-
ruses. There has been no report about the influenza-re-
lated viral resistance of ribavirin, which may be related
to its unique mechanism of action.17-19 A recent study
has indicated that the combination of oseltamivir,
amantadine and ribavirin has a high degree of synergy
in inhibiting viral replication. Also, this regime greatly
reduces side effects because of the low dose required
for each drug.20
Reduning is composed of Artemisia carvifolia,
Lonicera japonica Thunb, and Gardenia jasminoides
Ellis. Artemisia carvifolia is spicy, bitter and cold, with
the function of clearing heat and removing toxins ac-
cording to the theory of Traditional Chinese Medicine.
Reduning exhibits a strong neuraminidase inhibitory
activity in vitro neuraminidase inhibitor model. In ad-
dition, Reduning can also significantly reduce the lev-
els of IL-8, TNF-α as well as other proinflammatory
cytokines in the plasma and BALFs, which may have a
role in decreasing the severity of pulmonary edema and
improving the pathological changes of acute lung inju-
ry.21
Our study showed that Reduning alleviated pulmonary
edema and suppressed expression of IL-6 and IL-10 in
the BALFs of mice infected with BJ501. However, it
did not decrease virus titer nor prevent mortality, sug-
gesting limited protection against severe influenza. In
contrast, ribavirin as a prophylactic antiviral drug sig-
nificantly decreased virus titer and reduced lung edema
but failed to prevent lung injury. It was found that,
even though virus replication had been suppressed by
ribavirin, infection remained. This remaining infection
could trigger the cytokine storm and drive immuno-
pathological progression. When combined, ribavirin
and Reduning showed primarily additive interactions.
Mice treated with both drugs had minimal weight loss
and lung injury and significant suppression of IL-6
and IL-10 in BALF compared with ribavirin alone.
The synergistic effect of the two drugs was clearly more
effective than either one administered separately.
This study suggests that Reduning might enhance the
activity of ribavirin with an anti-inflammatory mecha-
nism that decreases the production of IL-6 and IL-10
during the early stages of pH1N1(2009) infection. The
current data provide an important reference for the
combined application of traditional Chinese com-
pounds and antiviral treatments in clinical practice
which is helpful for prevention of drug resistant vari-
ants in clinical investigations.
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